A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

NCT05262023 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Frontotemporal Dementia

Interventions

DRUG: DNL593
DRUG: Placebo

Sponsor

Denali Therapeutics Inc.

Collaborators

[object Object]